Literature DB >> 26751829

Phenotyping Rh/Kell and risk of alloimmunization in haematological patients.

F Baía1, F Correia1, B Alves1, F Martinez1, C Koch1, A Carneiro2, F Araújo1.   

Abstract

BACKGROUND: One of the biggest concerns in transfusion medicine is to avoid red blood cell alloimmunization. We evaluated the rate of alloimmunization in two groups of chronically transfused patients (A - not phenotyped and B - phenotyped for Rh/K antigens before the first transfusion) with primary haematological disorders and its distribution among the main haematological diseases, in order to adopt an efficient transfusional strategy. STUDY DESIGN AND METHODS: As methodology, we used the SIBAS and SAM databases for the retrospective study of all patients with primary haematological disorder between January 2011 and April 2013.
RESULTS: A statistical difference in the rate of alloimmunization comparing groups A and B was found (P <0·0001). We also observed that alloimmunization was not homogeneously distributed in all primary haematological diseases.
CONCLUSIONS: The Rh/K phenotype should be performed on all patients diagnosed with bone marrow failure, plasma cell dyscrasia and myelodysplastic syndrome in order to avoid alloimmunization. In patients with acute leukaemia and lymphoma it seems not necessary to perform it. In patients with haemoglobinopathy and myeloproliferative disorders, a larger group of patients is needed to decide its efficacy.
© 2016 British Blood Transfusion Society.

Entities:  

Keywords:  alloimmunization; cell transfusion; primary haematological disorder; red blood

Mesh:

Substances:

Year:  2016        PMID: 26751829     DOI: 10.1111/tme.12271

Source DB:  PubMed          Journal:  Transfus Med        ISSN: 0958-7578            Impact factor:   2.019


  3 in total

1.  A clinical effect of disease-modifying treatment on alloimmunisation in transfused patients with myelodysplastic syndromes: data from a population-based study.

Authors:  Johanne Rozema; Christiaan L Slim; Nic J G M Veeger; Robby E Kibbelaar; Harry de Wit; Eric N van Roon; Mels Hoogendoorn
Journal:  Blood Transfus       Date:  2020-12-16       Impact factor: 3.443

Review 2.  Prevalence and specificity of red blood cell alloantibodies and autoantibodies in transfused Iranian β-thalassemia patients: A systematic review and meta-analysis.

Authors:  Hosein Rostamian; Ehsan Javandoost; Mozhdeh Mohammadian; Abbas Alipour
Journal:  Asian J Transfus Sci       Date:  2022-05-26

3.  An Easy Multiplex PCR-SSP Assay for the Genotyping of KEL1 and KEL2 in Multi-transfused Patients.

Authors:  Parinaz Zarghamian; Maryam Pourshadlou; Kamran Mousavi Hosseini; Fariba Sarem; Majid Shahabi
Journal:  Indian J Hematol Blood Transfus       Date:  2021-01-01       Impact factor: 0.915

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.